Citigroup
SMMT icon

Citigroup’s Summit Therapeutics SMMT Stock Holding History

Citigroup’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4M Buy
236,800
+206,800
+689% +$3.09M ﹤0.01% 2276
2026
Q2 		$437K Sell
30,000
-120,800
-80% -$2.14M ﹤0.01% 3970
2026
Q1 		$2.86M Buy
+150,800
New +$2.44M ﹤0.01% 2419
2025
Q2 		– Sell
-15,000
Closed -$289K – 5888
2025
Q1 		$289K Buy
+15,000
New +$301K ﹤0.01% 3984

Other funds holding SMMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Hohimer Wealth Management
Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Griffin Asset Management
Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return

Citigroup's SMMT Position: Q3 2026 in Review

Citigroup reduced its Summit Therapeutics (SMMT) stake by 29% in Q3 2026, selling an estimated $3.05M and leaving 510,193 shares worth $8.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Citigroup first reported a position in SMMT in Q2 2015 and has held it in 38 quarters since. The position peaked at $10.4M in Q2 2026. 141 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Citigroup held 510,193 shares of Summit Therapeutics worth $8.63M as of Q3 2026.
  • Citigroup sold 203,807 Summit Therapeutics shares in Q3 2026, an estimated $3.05M.
  • Summit Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1742 holding.
  • Citigroup first reported a position in Summit Therapeutics in Q2 2015 and has held it in 38 quarters since.
  • Citigroup's Summit Therapeutics position peaked at $10.4M in Q2 2026.
  • 141 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.